Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR)‘s stock had its “hold” rating reiterated by equities researchers at HC Wainwright in a report released on Monday, Stock Target Advisor reports.
A number of other brokerages have also commented on TRIL. Cowen reissued a “buy” rating on shares of Trillium Therapeutics in a report on Thursday, August 15th. Zacks Investment Research lowered Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 25th.
Shares of NASDAQ TRIL opened at $0.28 on Monday. The firm has a market cap of $7.80 million, a price-to-earnings ratio of -0.12 and a beta of 2.18. The business’s 50-day simple moving average is $0.28 and its 200-day simple moving average is $0.36. Trillium Therapeutics has a 52 week low of $0.24 and a 52 week high of $3.20.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: Why do companies issue monthly dividends?
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.